CN Patent

CN101827611B — Ⅱ型抗CD20抗体在制备用于与抗Bcl-2活性剂联合治疗表达CD20的癌症的药物中的应用

Assigned to Roche Glycart AG · Expires 2014-01-15 · 12y expired

What this patent protects

本发明涉及II型抗CD20抗体在制备用于与抗Bcl-2活性剂联合治疗癌症，尤其是表达CD20的癌症的药物中的应用。

USPTO Abstract

本发明涉及II型抗CD20抗体在制备用于与抗Bcl-2活性剂联合治疗癌症，尤其是表达CD20的癌症的药物中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN101827611B
Jurisdiction
CN
Classification
—
Expires
2014-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Roche Glycart AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.